VIXARELIMAB, a monoclonal antibody targeting the oncostatin M receptor β, demonstrated significant and sustained clinical benefit in patients with moderate to severe prurigo nodularis (PN), according to results from a phase 2b randomised…
VIXARELIMAB, a monoclonal antibody targeting the oncostatin M receptor β, demonstrated significant and sustained clinical benefit in patients with moderate to severe prurigo nodularis (PN), according to results from a phase 2b randomised…